Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer

Naiqing Xu; Wenfeng Fang; Libing Mu; Yanna Tang; Lei Gao; Shengxiang Ren; Dengfeng Cao; Lixin Zhou; Aiqun Zhang; Deruo Liu; Caicun Zhou; Kwok-Kin Wong; Lei Yu; Li Zhang; Liang Chen

doi:10.18632/oncotarget.26254

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer

PDF | How to cite

Oncotarget. 2018; 9:35284-35284. https://doi.org/10.18632/oncotarget.26254

Metrics: PDF 1508 views | ?

Naiqing Xu^1,2,3,*, Wenfeng Fang^4,*, Libing Mu⁵, Yanna Tang⁴, Lei Gao², Shengxiang Ren⁶, Dengfeng Cao⁷, Lixin Zhou⁸, Aiqun Zhang⁹, Deruo Liu¹⁰, Caicun Zhou⁶, Kwok- Kin Wong¹¹, Lei Yu¹², Li Zhang⁴ and Liang Chen^1,2,3,13

¹ Graduate School of Peking Union Medical College, Beijing, China
² National Institute of Biological Sciences, Beijing, China
³ Chinese Academy of Medical Sciences, Beijing, China
⁴ Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, P. R. China
⁵ Tsinghua University School of Medicine, Beijing, China
⁶ Shanghai Pulmonary Hospital, Shanghai, China
⁷ Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing, China
⁸ Peking University Cancer Hospital, Beijing, China
⁹ General Hospital of People’s Liberation Army, Beijing, China
¹⁰ Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China
¹¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
¹² Beijing Tongren Hospital, Capital Medical University, Beijing, China
¹³ National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, China
^* These author have contributed equally to this work

Published: October 16, 2018

This article has been corrected: The correct Grant Support information is given below:

GRANT SUPPORT

This work was funded by National Natural Science Foundation of China grant 81472606, Chinese Ministry of Science and Technology grant (973 grant) 2011CB812401, and the Beijing Municipal Government.

Original article: Oncotarget. 22016; 7:3884-3896. DOI: https://doi.org/10.18632/oncotarget.6461.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26254

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer